Pros and cons of treating murine myasthenia gravis with anti-C1q antibody

J Neuroimmunol. 2007 Jan;182(1-2):167-76. doi: 10.1016/j.jneuroim.2006.10.014. Epub 2006 Nov 29.

Abstract

To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 microg or 100 microg of anti-C1q Ab or isotype Ab. Treatment with 10 microg anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 microg anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies / blood
  • Antibodies / pharmacology*
  • Antigen-Antibody Complex / blood
  • B-Lymphocytes / pathology
  • Complement C1q / immunology*
  • Complement C3 / metabolism
  • Complement System Proteins / metabolism
  • Feasibility Studies
  • Immunoglobulin G / metabolism
  • Interleukin-6 / biosynthesis*
  • Kidney / metabolism
  • Lymph Nodes / metabolism
  • Lymph Nodes / pathology
  • Mice
  • Mice, Inbred Strains
  • Myasthenia Gravis / immunology
  • Myasthenia Gravis / metabolism
  • Myasthenia Gravis / pathology*
  • Myasthenia Gravis / physiopathology*
  • Receptors, Cholinergic / immunology
  • Severity of Illness Index
  • T-Lymphocytes / pathology*
  • Torpedo

Substances

  • Antibodies
  • Antigen-Antibody Complex
  • Complement C3
  • Immunoglobulin G
  • Interleukin-6
  • Receptors, Cholinergic
  • Complement C1q
  • Complement System Proteins